Servier partners with Innovative Medicines Canada Members to Donate 100,000 Masks to Help Protect Front-Line Healthcare Workers Battling COVID-19
LAVAL, QC, April 2, 2020 /CNW Telbec/ - Servier Canada, along with other pharmaceutical companies, members of Innovative Medicines Canada (IMC), are continuing their efforts in the fight against COVID-19 by donating 100,000 N95 masks for front-line healthcare workers battling the virus. The donation is in response to the federal government's request for additional protective equipment.
"As a leading company in Health and Life Sciences, Servier's very first thoughts go to the front-line medical community. Healthcare workers are operating every day within clinics and hospitals to relieve patients suffering from COVID-19, often at the cost of their own safety. Through this donation, we want to help to protect them and to bring our own contribution to the fight against the virus", said Servier Canada's CEO Frederic Fasano.
"Our industry will continue to collaborate with all levels of government, with civil society groups and with each other in unprecedented ways in response to this crisis", said IMC President Pamela Fralick. "Our members are playing a leading role in Canada and around the world in the race to find effective treatments, better diagnostic tools, and to create vaccines to help identify, treat and ultimately, stop the spread of COVID-19", she added.
The donation is one of several initiatives supported by Servier to contribute to the fight against the pandemic on the ground. "In Canada, as well as in many other affected countries, Servier is providing personal protection equipment to hospitals and is making donations to foundations and NGOs. In France, the location of Servier's Global headquarters, many healthcare professionals employed by Servier have volunteered and have been made available to health authorities to join medical staff on the front-line against the virus. We at Servier consider this contribution as part of our mission and responsibility", said Frédéric Fasano. "Servier also puts its best efforts to ensure the continuity of its manufacturing and supply operations in order for its medicines to remain available to Canadian patients who rely on them", he added.
To learn more about what Canada's innovative medicines companies are doing please visit http://innovativemedicines.ca/coronavirus-working-together-solution/.
About Servier Canada
Servier Canada is the Canadian affiliate of Servier Group, an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 149 countries and a turnover of 4.6 billion euros in 2019, Servier employs 22,000 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (excluding generic drugs) in research and development and uses all its profits for development. Corporate growth is driven by Servier's constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neuropsychiatric diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development. Servier has been present in Canada since 1978.
More information is available at www.servier.ca
SOURCE Servier Canada Inc.
